NAD⁺ Anti-Aging Combination Brings Dual Improvements in Cognition and Vitality for Senior Dogs
Introduction:
As time quietly passes, have you noticed your once lively dog becoming slower to respond or experiencing disrupted sleep? Don’t worry — science is bringing new hope! The latest clinical trial has confirmed that a combination of NAD⁺ precursors, which targets the core mechanisms of aging, can significantly improve cognitive function in senior dogs. This is not only a major breakthrough in the field of pet anti-aging but also offers a brand-new perspective for human longevity research.
As pets age, their slowing movements and cognitive decline become a source of worry for many owners. These changes are closely linked to cellular aging and the depletion of NAD⁺, a key energy molecule in the body. So, is there a scientific and safe way to help our furry companions fight against time and preserve their vitality?
PART 01
Scientific Evidence: A Randomized Controlled Trial Confirms That an NAD⁺ Combination Improves Cognitive Function in Dogs
Recently, a randomized, double-blind, placebo-controlled clinical study published in Scientific Reports delivered exciting results. Led by a top North American veterinary research team, the study evaluated the effects of a compound supplement called LY-D6/2—a combination of a novel senolytic agent and an NAD⁺ precursor—on cognitive function and activity levels in senior dogs.
A total of 70 elderly dogs (≥10 years old) with mild to moderate cognitive impairment were enrolled and randomly assigned to one of three groups: a full-dose LY-D6/2 group, a low-dose LY-D6/2 group, and a placebo group. The dogs were monitored over a period of six months.
Key Findings: Owner Assessments Show Significant Cognitive Improvement
.The primary endpoint of the study was the change in Canine Cognitive Dysfunction Rating (CCDR) scores at 3 months. The results clearly demonstrated that:
.The full-dose supplementation group showed the greatest reduction in CCDR scores, indicating the most significant cognitive improvement.
.Statistical analysis revealed a significant difference in improvement among the treatment groups (p = 0.02), and the effect followed a dose-dependent trend.
As many as 88.9% of the dogs in the full-dose group showed stable or improved cognitive status, compared with 60% in the placebo group.
Beyond Cognition: Potential Improvements in Vitality and Well-Being
In addition to objective data, the study also revealed several positive trends. Although activity monitoring did not show statistically significant differences between groups, owner feedback indicated that:
More owners in the full-dose group reported increased activity levels and enhanced overall well-being in their dogs.
More dogs in this group showed improvement or stabilization in frailty status, suggesting broader health benefits.
These results indicate that the LY-D6/2 combination may gently improve the quality of life for senior dogs across multiple dimensions.
Safe and Reliable, Giving Pet Owners Peace of Mind
For any pet supplement, safety is always the top priority. This study conducted rigorous safety monitoring:
Most adverse events were mild (VCOG Grade 1) and resolved on their own without intervention.
Serious health events reported during the study were assessed as unrelated to the supplement and were mainly due to underlying age-related conditions in the senior dogs.
PART 02
Why Choose NAD⁺? A Cutting-Edge Strategy for Scientific Anti-Aging
This study adopts a “dual-action” scientific anti-aging strategy:
Supplementing senolytics: These agents help clear “zombie cells”—senescent cells that stop dividing and release harmful substances—thereby reducing inflammation and creating conditions that support tissue regeneration. Ingredients such as quercetin fall into this category.
Supplementing NAD⁺ precursors: These compounds replenish NAD⁺, a key energy molecule that declines with age. By restoring NAD⁺ levels, they support cellular energy metabolism, enhance DNA repair, activate longevity proteins, and reignite cellular vitality.
The combination of these two approaches is theoretically synergistic. This study demonstrates promising clinical potential for applying this strategy in pets—and the results are truly encouraging!
PART 03
Give Your Beloved Pet a Smarter, More Vibrant Senior Life
This groundbreaking clinical trial demonstrates that LY-D6/2 (a combination of a senolytic agent and an NAD⁺ precursor) can safely and effectively improve owner-assessed cognitive function in senior dogs, while also showing potential to enhance their overall vitality and well-being. It offers a new, clinically validated solution for addressing pet aging through scientific and evidence-based approaches.
Don’t let cognitive decline steal the precious moments you share with your beloved pet. Stay informed about cutting-edge NAD⁺ anti-aging science and choose a scientifically validated health-support solution for your “family member.” Together, you can look forward to a future that is brighter, sharper, and full of vitality!
As time quietly passes, have you noticed your once lively dog becoming slower to respond or experiencing disrupted sleep? Don’t worry — science is bringing new hope! The latest clinical trial has confirmed that a combination of NAD⁺ precursors, which targets the core mechanisms of aging, can significantly improve cognitive function in senior dogs. This is not only a major breakthrough in the field of pet anti-aging but also offers a brand-new perspective for human longevity research.
PART 01
Scientific Evidence: A Randomized Controlled Trial Confirms That an NAD⁺ Combination Improves Cognitive Function in Dogs
Recently, a randomized, double-blind, placebo-controlled clinical study published in Scientific Reports delivered exciting results. Led by a top North American veterinary research team, the study evaluated the effects of a compound supplement called LY-D6/2—a combination of a novel senolytic agent and an NAD⁺ precursor—on cognitive function and activity levels in senior dogs.
A total of 70 elderly dogs (≥10 years old) with mild to moderate cognitive impairment were enrolled and randomly assigned to one of three groups: a full-dose LY-D6/2 group, a low-dose LY-D6/2 group, and a placebo group. The dogs were monitored over a period of six months.
Key Findings: Owner Assessments Show Significant Cognitive Improvement
.The primary endpoint of the study was the change in Canine Cognitive Dysfunction Rating (CCDR) scores at 3 months. The results clearly demonstrated that:
.The full-dose supplementation group showed the greatest reduction in CCDR scores, indicating the most significant cognitive improvement.
.Statistical analysis revealed a significant difference in improvement among the treatment groups (p = 0.02), and the effect followed a dose-dependent trend.
As many as 88.9% of the dogs in the full-dose group showed stable or improved cognitive status, compared with 60% in the placebo group.
Beyond Cognition: Potential Improvements in Vitality and Well-Being
In addition to objective data, the study also revealed several positive trends. Although activity monitoring did not show statistically significant differences between groups, owner feedback indicated that:
More owners in the full-dose group reported increased activity levels and enhanced overall well-being in their dogs.
More dogs in this group showed improvement or stabilization in frailty status, suggesting broader health benefits.
These results indicate that the LY-D6/2 combination may gently improve the quality of life for senior dogs across multiple dimensions.
Safe and Reliable, Giving Pet Owners Peace of Mind
For any pet supplement, safety is always the top priority. This study conducted rigorous safety monitoring:
Most adverse events were mild (VCOG Grade 1) and resolved on their own without intervention.
Serious health events reported during the study were assessed as unrelated to the supplement and were mainly due to underlying age-related conditions in the senior dogs.
PART 02
Why Choose NAD⁺? A Cutting-Edge Strategy for Scientific Anti-Aging
This study adopts a “dual-action” scientific anti-aging strategy:
Supplementing senolytics: These agents help clear “zombie cells”—senescent cells that stop dividing and release harmful substances—thereby reducing inflammation and creating conditions that support tissue regeneration. Ingredients such as quercetin fall into this category.
Supplementing NAD⁺ precursors: These compounds replenish NAD⁺, a key energy molecule that declines with age. By restoring NAD⁺ levels, they support cellular energy metabolism, enhance DNA repair, activate longevity proteins, and reignite cellular vitality.
The combination of these two approaches is theoretically synergistic. This study demonstrates promising clinical potential for applying this strategy in pets—and the results are truly encouraging!
PART 03
Give Your Beloved Pet a Smarter, More Vibrant Senior Life
This groundbreaking clinical trial demonstrates that LY-D6/2 (a combination of a senolytic agent and an NAD⁺ precursor) can safely and effectively improve owner-assessed cognitive function in senior dogs, while also showing potential to enhance their overall vitality and well-being. It offers a new, clinically validated solution for addressing pet aging through scientific and evidence-based approaches.
